enVVeno Medical 미래 성장

Future 기준 확인 2/6

enVVeno Medical은 연간 수입과 매출이 각각 32.9%와 96.7% 증가할 것으로 예상되고 EPS는 연간 41.7%만큼 증가할 것으로 예상됩니다.

주요 정보

32.9%

수익 성장률

41.7%

EPS 성장률

Medical Equipment 수익 성장	17.1%
매출 성장률	96.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	06 Aug 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

수익 및 매출 성장 예측

NasdaqCM:NVNO - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	22	-19	N/A	-7	1
12/31/2025	4	-25	N/A	7	1
12/31/2024	N/A	-22	N/A	-24	1
9/30/2024	N/A	-21	-17	-17	N/A
6/30/2024	N/A	-21	-17	-17	N/A
3/31/2024	N/A	-22	-17	-17	N/A
12/31/2023	N/A	-24	-19	-19	N/A
9/30/2023	N/A	-24	-18	-18	N/A
6/30/2023	N/A	-25	-18	-18	N/A
3/31/2023	N/A	-26	-17	-17	N/A
12/31/2022	N/A	-25	-16	-16	N/A
9/30/2022	N/A	-27	-15	-15	N/A
6/30/2022	N/A	-24	-13	-13	N/A
3/31/2022	N/A	-19	-12	-11	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-12	-12	-11	N/A
6/30/2021	N/A	-12	-12	-12	N/A
3/31/2021	N/A	-11	-11	-10	N/A
12/31/2020	N/A	-10	-8	-8	N/A
9/30/2020	N/A	-7	-7	-7	N/A
6/30/2020	N/A	-7	-6	-5	N/A
3/31/2020	N/A	-7	-6	-6	N/A
12/31/2019	0	-8	-6	-6	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-7	-6	-6	N/A
3/31/2019	0	-13	-6	-6	N/A
12/31/2018	0	-16	-6	-6	N/A
9/30/2018	0	-18	-6	-6	N/A
6/30/2018	0	-19	N/A	-6	N/A
3/31/2018	0	-12	N/A	-5	N/A
12/31/2017	0	-8	N/A	-4	N/A
9/30/2017	1	-7	N/A	-4	N/A
6/30/2017	1	-5	N/A	-3	N/A
3/31/2017	1	-6	N/A	-3	N/A
12/31/2016	1	-6	N/A	-3	N/A
9/30/2016	0	-5	N/A	-4	N/A
12/31/2015	N/A	-1	N/A	-2	N/A
12/31/2014	0	-1	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NVNO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: NVNO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: NVNO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: NVNO 의 수익(연간 96.7% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: NVNO 의 수익(연간 96.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NVNO 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

enVVeno Medical 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target decreased by 15% to US$20.40

Price target decreased to US$24.00

No longer forecast to breakeven

Price target decreased to US$26.00

Recent updates

enVVeno Medical Corporation, Annual General Meeting, Dec 18, 2024

Envveno Medical Successfully Initiates 6-Month Pre-Clinical Glp Study Evaluating Envve(R)

New major risk - Shareholder dilution

New minor risk - Share price stability

enVVeno Medical Corporation has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial

enVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견